© 2013 Therapharm a.s.
The subject of current production, research and development (R&D) is the development of components for a building of the
targeted drugs and targeted therapeutic agents focused on the treatment of various forms of carcinomas (cancer therapy) in state of their genesis (
cancer stem cells or primary cancer cells), also
cancer stem cells' subpopulation with ability to migrate (metastazis or
metastatic cancer stem cells) and highly controlled
stem cell therapy (tissue engineering as neoplastics). Our components for a building of the targeted therapeutic agents are mainly based on peptides (usually from 25 to 35 AAs) and by third parties there is possible to use these components as targeting supramolecules or biological addresses for seeking of the targeted tissue in human organism. Such a futuristic exemplar therapeutic agent is based on a hydrophilic carrier of the type of a spherical nanocapsule. Its filling with a biologically active substance, especially a substance of a hydrophilic nature (peptide), happens by means of diffusion through a circular opening in the nanocapsule wall. In the therapeutic agent the nanocapsule may be filled with Therapharm's peptide receptor modulators and, depending on whether the modulation is positive (proliferators, growth factors, receptor stimulators) the result is a therapeutic agent for highly controlled treatment with stem cells, or negative (receptor blockers), in which case the result is a therapeutic agent for treatment of various forms of cancer. Nanocapsules can carry a variety of externalities, generally called receptor-active sites, which find their target in the organism themselves, or, eventually, nanocapsules are placed directly into the stem cell niche.